Match!
Michael Gowen
New York University
4Publications
2H-index
27Citations
Publications 4
Newest
Published on Dec 1, 2018in Journal of Translational Medicine4.10
Michael Gowen2
Estimated H-index: 2
(NYU: New York University),
Keith M. Giles22
Estimated H-index: 22
(NYU: New York University)
+ 11 AuthorsMelissa Wilson9
Estimated H-index: 9
(NYU: New York University)
Background Immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, or the combination) enhance anti-tumor immune responses, yielding durable clinical benefit in several cancer types, including melanoma. However, a subset of patients experience immune-related adverse events (irAEs), which can be severe and result in treatment termination. To date, no biomarker exists that can predict development of irAEs.
Published on Oct 1, 2018in Annals of Oncology14.20
Danny Simpson3
Estimated H-index: 3
(NYU: New York University),
FergusonRobert9
Estimated H-index: 9
(NYU: New York University)
+ 13 AuthorsShaohui Hu13
Estimated H-index: 13
Published on May 20, 2017in Journal of Clinical Oncology28.25
Michael Gowen2
Estimated H-index: 2
(NYU: New York University),
Jeremy Tchack3
Estimated H-index: 3
(NYU: New York University)
+ 9 AuthorsAnna C. Pavlick42
Estimated H-index: 42
(NYU: New York University)
Published on Apr 11, 2017in Oncotarget
Marianna Vitiello1
Estimated H-index: 1
(UniPi: University of Pisa),
Andrea Tuccoli6
Estimated H-index: 6
(UniPi: University of Pisa)
+ 33 AuthorsChiara Ippolito14
Estimated H-index: 14
(UniPi: University of Pisa)
// Marianna Vitiello 1, 2 , Andrea Tuccoli 1 , Romina D’Aurizio 3 , Samanta Sarti 1, 4 , Laura Giannecchini 1 , Simone Lubrano 1, 4 , Andrea Marranci 1, 4 , Monica Evangelista 2 , Silvia Peppicelli 5 , Chiara Ippolito 6 , Ivana Barravecchia 7 , Elena Guzzolino 7 , Valentina Montagnani 8 , Michael Gowen 9 , Elisa Mercoledi 1 , Alberto Mercatanti 2 , Laura Comelli 2 , Salvatore Gurrieri 1 , Lawrence W. Wu 10 , Omotayo Ope 10 , Keith Flaherty 11 , Genevieve M. Boland 11 , Marc R. Hammond 11 , Lawre...
1